REMS Assessment Review Goals, Resources On The Table For PDUFA VII

US FDA proposes formal performance metrics for REMS assessment reviews, which would be part of a larger campaign to streamline the REMS assessment process.

Risk versus value matrix with pushpins and blur effect. Concept of investment risk assessment.
The FDA wants more PDUFA resources devoted to the REMS program to help speed up REMS assessment reviews. • Source: Shutterstock

Risk Evaluation and Mitigation Strategy assessments may be subject to performance goals under the next prescription drug user fee program.

Food and Drug Administration officials also have indicated they want funding to speed up the REMS assessment process. As part...

More from User Fees

US FDA Could Miss User Fee Spending Triggers With House FY 2026 Funding

 

FDA employees are concerned that while the budget authority total proposed for fiscal year 2026 meets the user fee appropriations' triggers, the FDA could have trouble meeting allocation triggers without cuts to non-review work.

US FDA’s Rising First-Cycle Complete Response Rate Draws Congress’ Attention

 
• By 

The House Appropriations Committee wants an analysis of how issues that led to CRLs could have been resolved within the first review cycle and seeks an agency crackdown on counterfeit GLP-1 agonists.

Generic Drug Office’s Policy Staff Returning To US FDA

 

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

House Gives US FDA More Non-User Fee Funds Than Requested

 

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.

More from Pathways & Standards